

STEMCELLS INC
Form 8-K
November 12, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to
Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 11, 2003

STEMCELLS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-19871
(Commission File Number)

94-3078125
(I.R.S. Employer
Identification Number)

3155 Porter Drive
Palo Alto, California 94304

(Address, of principal executive offices, including zip code)

(650) 475-3100

(Registrant's Telephone number including area code)

TABLE OF CONTENTS

Item 5. OTHER EVENTS

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. OTHER EVENTS

On November 11, 2003, StemCells, Inc. (the Company) reported that Riverview Group, LLC (Riverview) exercised its right to convert the remaining shares of the Company's 3% Convertible Preferred stock held by Riverview. Riverview will receive 1,010,833 shares of the Company's common stock upon conversion of these shares of the Company's 3% Convertible Preferred Stock, including shares of common stock issued with respect to accrued and unpaid dividends.

In addition, on November 11, 2003 the Company reported that Riverview exercised a warrant to purchase shares of the Company's common stock. This warrant entitles Riverview to purchase up to 1,898,000 shares of the Company's common stock on the terms set forth in the warrant at a price of \$1.50 per share. Riverview exercised the warrant with respect to 1,098,000 shares of common stock and the Company will receive an aggregate exercise price of \$1,647,000. The warrant will remain exercisable for 800,000 shares of the Company's common stock in accordance with the terms of the warrant.

A copy of the Company's press release announcing the transactions described above is attached as Exhibit 99.1 to this Report and is incorporated in this Report by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEMCELLS, INC

By: /s/ Martin McGlynn

Martin McGlynn
President and Chief Executive Officer

Date: November 11, 2003

Table of Contents

EXHIBIT INDEX

99.1 Press release issued by StemCells, Inc. on November 11, 2003.

-4-